Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S383000, C514S397000
Reexamination Certificate
active
07863326
ABSTRACT:
Method for prevention and treatment of vaginal fungal infections by administering a formulation comprising ascorbic acid or a physiologically acceptable salt thereof to a patient in need of such prevention or treatment. The formulation is administered after completion of the standard treatment against bacterial, fungal or protozoarian infections.
REFERENCES:
patent: 4229430 (1980-10-01), Fahim et al.
patent: 5371107 (1994-12-01), Hotzel et al.
patent: 5631001 (1997-05-01), Harich et al.
patent: 6770306 (2004-08-01), Zeng
patent: 299 00 513 (2000-10-01), None
patent: 0 527 241 (1993-02-01), None
patent: 1 153 605 (2001-11-01), None
Kerr. Bacterial inhbition of fungal growth and pathogenicity. Microbial Ecology in Health and Disease pp. 129-142. Scandianavian Univerty Press 1999, ISSN 0891-060X.
Patent Abstracts of Japan, vol. 2000, No. 09; “Dermatosis Therapeutic Agent and Health Food for Carnivorous Animal”, Oct. 13, 2000 & JP 2000 169370 A, Jun. 20, 2000 (abstract).
Patent Abstracts of Japan, vol. 013, No. 372; “Controlling Agent Against Red Rot Fungi”; Aug. 17, 1989 & JP 01 125306 A, May 17, 1989 (abstract).
Database WPI, Derwent Publications Ltd., London, GB; AN 2000-663199.(XP002266917) & RU 2 150 935 C (Univ Mosc Med Stomatology) Jun. 20, 2000 (abstract).
Database WPI, Derwent Publications Ltd., London, GB; AN 2003-002680 (XP002266918); “Antifungal medicinal preparation contains copper (I) oxide, elemental copper and optionally trace elements and ascorbic acid”; & HU 200 004 976 A; Oct. 28, 2002 (abstract).
Fortis, A.A., et al; “Adherence ofStaphylococcus aureus, Klebsiella pneumoniaeandCandida albicansto human buccal epithelial cells, from healthy persons and HIV carriers, under the influence of Broncho Vaxom in vitro and ascorbic acid in vivo”;ACTA Pathologica, Microbiologica, et Immunologica Scandinavica; vol. 106, No. 4, pp. 441-448 (Apr. 1998) XP009023968 (abstract).
IPER—Vagi-C leaflet; Taurus Pharma, Stand der information, Dec. 2000 (2 pgs).
IPER—Eiko E. Petersen; “Der Einsatz von Vitamin C (Vagi-C) zur Normalisierung der Vaginalflora”; Sounderdruck Gyne; 19, Jahrgang, Mar. 1998.
English translation of German Utility Model DE: 299 00 513 U1; RST Icking GmbH; “Hygiene Agent for Shoes or Feet” (5 pgs).
English translation of Eiko E. Petersen; “Aminocolpitis / Bacterial Vaginosis; Administration of Vitamin C (Vagi-C) for the Normalization of the Vaginal Flora”;A Journal for Practical Gynecology&General Medicine, vol. 19, Mar. 1998 (7 pgs).
English translation of Vagi-C leaflet; “Vagi-C®, Vaginal Tablets 250 mg (Ascorbic acid)” (9 pgs).
Runeman, B., et al; “The Vulva Skin Microclimate: Influence of Panty Liners on Temperature, Humidity and pH”;Acta Derm Venereol; vol. 83; pp. 88-92 (2003).
Runeman, B., et al; “ExperimentalCandida albicansLesions in Healthy Humans: Dependence on Skin pH”;Acta Derm Venereol; vol. 80; pp. 421-424 (2000).
Runeman, B., et al; “the Vulvar Skin Microenvironment: Influence of Different Panty Liners on Temperature, pH and Microflora”;Acta Derm Venereol; vol. 84; pp. 277-284 (2004).
Rogers, T.J., et al; “Dietary ascorbic acid and resistance to experimental renal candidiasis”;J. Nutr.; 113(1); pp. 178-183 (1983) (Abstract).
Martindale The complete drug reference; Thirty-third edition, Edited by Sean C. Sweetman; (3 pgs) (2002).
Sobel, J.D., “Vulvovaginal candidosis”; www.thelancet.com; vol. 369; pp. 1961-1971 (2007).
“Cyclopyroxolamine in the Treatment and Prevention of Vulvovaginal Mycoses”; Edited by A.R. Genazzani, et al; The Parthenon Publishing Group; Gorlero, F., et al; “Role of cyclopyroxolamine in mycotic vulvovaginitis: epidemiological prospective study”; pp. 53-64.
Education & Debate; Management of genital candidiasis;BMJ; vol. 310, pp. 1241-1244 (1995).
Kim Jennifer M
Nixon & Vanderhye
Polichem S.A.
LandOfFree
Pharmaceutical compositions comprising ascorbic acid for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising ascorbic acid for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising ascorbic acid for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688975